Methamphetamine-Associated Psychosis and Treatment With Haloperidol and Risperidone: A Pilot Study

Authors Information
Article Notes and Dates
Abstract
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Farnia V, Shakeri J, Tatari F, Juibari TA, Yazdchi K, Bajoghli H, et al. Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis. Am J Drug Alcohol Abuse. 2014; 40(1): 10-5[DOI][PubMed]
  • 2. Fasihpour B, Molavi S, Shariat SV. Clinical features of inpatients with methamphetamine-induced psychosis. J Ment Health. 2013; 22(4): 341-9[DOI][PubMed]
  • 3. Degenhardt L, Roxburgh A, McKetin R. Hospital separations for cannabis- and methamphetamine-related psychotic episodes in Australia. Med J Aust. 2007; 186(7): 342-5[PubMed]
  • 4. McKetin R, Kozel N, Douglas J, Ali R, Vicknasingam B, Lund J, et al. The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev. 2008; 27(3): 220-8[DOI][PubMed]
  • 5. Gonzales R, Ang A, McCann MJ, Rawson RA. An emerging problem: methamphetamine abuse among treatment seeking youth. Subst Abus. 2008; 29(2): 71-80[DOI][PubMed]
  • 6. Mordal J, Bramness JG, Holm B, Morland J. Drugs of abuse among acute psychiatric and medical admissions: laboratory based identification of prevalence and drug influence. Gen Hosp Psychiatry. 2008; 30(1): 55-60[DOI][PubMed]
  • 7. Cantor-Graae E, Nordstrom LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res. 2001; 48(1): 69-82[PubMed]
  • 8. Ringen PA, Melle I, Birkenaes AB, Engh JA, Faerden A, Vaskinn A, et al. The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness. Acta Psychiatr Scand. 2008; 118(4): 297-304[DOI][PubMed]
  • 9. Yeh HS, Lee YC, Sun HJ, Wan SR. Six months follow-up of patients with methamphetamine psychosis. Zhonghua Yi Xue Za Zhi (Taipei). 2001; 64(7): 388-94[PubMed]
  • 10. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci. 2004; 1025: 279-87[DOI][PubMed]
  • 11. Myers CS, Halladay AK, Widmer DA, Wagner GC. Neurotoxic effects of amphetamine plus L-DOPA. Prog Neuropsychopharmacol Biol Psychiatry. 1999; 23(4): 731-40[PubMed]
  • 12. Iyo M, Sekine Y, Mori N. Neuromechanism of developing methamphetamine psychosis: a neuroimaging study. Ann N Y Acad Sci. 2004; 1025: 288-95[DOI][PubMed]
  • 13. Chen CK, Lin SK, Sham PC, Ball D, Loh el W, Murray RM. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet. 2005; 136B(1): 87-91[DOI][PubMed]
  • 14. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull. 1992; 18(1): 115-22[PubMed]
  • 15. Hofmann F. A handbook on drug and alcohol abuse: the biomedical aspects. . 1983;
  • 16. Sato M, Chen CC, Akiyama K, Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry. 1983; 18(4): 429-40[PubMed]
  • 17. Srisurapanont M, Kittiratanapaiboon P, Jarusuraisin N. Treatment for amphetamine psychosis. Cochrane Database Syst Rev. 2001; (4): 3026[DOI][PubMed]
  • 18. Angrist B, Sathananthan G, Wilk S, Gershon S. Amphetamine psychosis: behavioral and biochemical aspects. J Psychiatr Res. 1974; 11: 13-23[PubMed]
  • 19. Richards JR, Derlet RW, Duncan DR. Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med. 1998; 16(4): 567-73[PubMed]
  • 20. Misra LK, Kofoed L, Oesterheld JR, Richards GA. Olanzapine treatment of methamphetamine psychosis. J Clin Psychopharmacol. 2000; 20(3): 393-4[PubMed]
  • 21. Misra L, Kofoed L. Risperidone treatment of methamphetamine psychosis. Am J Psychiatry. 1997; 154(8): 1170[PubMed]
  • 22. Dore G, Sweeting M. Drug-induced psychosis associated with crystalline methamphetamine. Australas Psychiatry. 2006; 14(1): 86-9[DOI][PubMed]
  • 23. Morefield K, Ali R, Baigent M, Christie P, Pointer S, Danz C. Methamphetamine Psychosis in South Australia: Stage 1 of Methamphetamine Psychosis Research Program. Adelaide, South Australia: Drug and Alcohol Services Council. DASC Monogragh. 2004; 11
  • 24. Paparelli A, Di Forti M, Morrison PD, Murray RM. Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci. 2011; 5: 1[DOI][PubMed]
  • 25. Alibeygi N. The effectiveness of cognitive-behavioral treatment and cognitive rehabilitation in reducing symptoms and recovery of Schizophrenic patients (in persian). 2010;
  • 26. Andreasen NC. The scale for the assessment of positive symptoms (SAPS). 1984;
  • 27. Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry. 1999; 60 Suppl 10: 52-60[PubMed]
  • 28. Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis--preliminary observations. Biol Psychiatry. 1970; 2(2): 95-107[PubMed]
  • 29. Tomiyama G. Chronic schizophrenia-like states in methamphetamine psychosis. Jpn J Psychiatry Neurol. 1990; 44(3): 531-9[PubMed]
  • 30. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry. 2002; 51(12): 972-8[PubMed]
  • 31. Markianos M, Hatzimanolis J, Lykouras L. Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Psychopharmacology (Berl). 1999; 143(3): 270-2[PubMed]
  • 32. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int Clin Psychopharmacol. 2001; 16(6): 325-30[PubMed]
  • 33. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993; 13(1): 25-40[PubMed]
  • 34. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, et al. Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat. 2008; 35(4): 445-50[DOI][PubMed]
  • 35. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004; 185: 196-204[DOI][PubMed]
  • 36. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004; 13(2): 181-90[DOI][PubMed]
  • 37. Sato M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann N Y Acad Sci. 1992; 654: 160-70[PubMed]

Mazandaran University of Medical Sciences accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check